Multiple risk factors have been recognized as potential contributors for cardiovascular disease (CVD) in diabetic patients including hyperglycemia, elevated glycated hemoglobin (HbA1c) concentrations, hyperinsulinemia, hypertension, obesity, hypercholesterolemia, hypertriglyceridemia, and smoking. ConclusionįAS might be beneficial for reducing homocysteine and sortilin levels, enhancing glycemic control, and improved insulin resistance in patients with T2DM.ĭiabetes mellitus is one of the extremely common chronic ailments in nearly all countries and major health care problem worldwide. There were no significant changes in lipid profile in both groups after 12 weeks. After 3 months of intervention, 8.7% decrease in fasting blood glucose ( P = 0.0005), 8.2% in HbA1c ( P = 0.0002), 13.7% in serum insulin ( P < 0.0001) and 21.7% in insulin resistance ( P < 0.0001) were found in the folic acid group, however no significant difference was observed in the placebo group.
ResultsįAS caused a significant decrease in homocysteine and sortilin serum levels (28.2% and 33.7%, P < 0.0001, respectively).
#Side effect of metformin trial
MethodĪ double-blind randomized controlled clinical trial have been performed on 100 patients with T2DM randomly divided into two groups that received either placebo or folic acid 5 mg/d for 12 weeks. The present study aimed to determine the folic acid supplement (FAS) effects on serum homocysteine and sortilin levels, glycemic indices, and lipid profile in type II diabetic patients.
0 kommentar(er)
